Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type III error

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Type III error. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2022-000899-19 Sponsor Protocol Number: EVX-01-001 Start Date*: 2022-09-16
    Sponsor Name:Evaxion Biotech A/S
    Full Title: An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma
    Medical condition: unresectable or metastatic melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004868-69 Sponsor Protocol Number: AP7000_1-4002 Start Date*: 2005-03-07
    Sponsor Name:ZLB Behring LLC
    Full Title: Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease
    Medical condition: Von Willebrand’s disease (VWD) is a common hereditary bleeding disorder. The impaired formation and adhesion of the initial platelet plug is reflected in the prolonged skin bleeding time. In addit...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10047715 LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004359-57 Sponsor Protocol Number: CanStem111P Start Date*: 2017-08-01
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
    Medical condition: This study will enroll patients with histologically or cytologically confirmed adenocarcinoma of the pancreas that is metastatic (Stage IV).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005874-11 Sponsor Protocol Number: 0822-035 Start Date*: 2009-02-24
    Sponsor Name:Laboratoires Merck Sharp & Dhome-Chibret
    Full Title: A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of ...
    Medical condition: This is an exploratory sub-study of Protocol 018 (Eudract N°2007-002693-66) to identify biomarkers of physical function. This biomarker sub-study will use an ongoing clinical study (Protocol 018) ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031283 Osteoporosis fracture LLT
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002316-10 Sponsor Protocol Number: H6Q-MC-S019(b) Start Date*: 2006-10-09
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatmen...
    Medical condition: Patients with a histologic diagnosis of FIGO Stage IIB, IIC, III, or IV advanced invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001236-65 Sponsor Protocol Number: GS-US-312-0119 Start Date*: 2013-01-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) GB (Completed) SE (Completed) ES (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000199-12 Sponsor Protocol Number: A011-13 Start Date*: 2022-07-19
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and Hig...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Prematurely Ended) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2019-002463-10 Sponsor Protocol Number: BLU-667-2303 Start Date*: 2020-05-28
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
    Medical condition: RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NO (Trial now transitioned) FI (Completed) BE (Trial now transitioned) DE (Prematurely Ended) PL (Trial now transitioned) CZ (Prematurely Ended) NL (Trial now transitioned) PT (Trial now transitioned) DK (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002326-11 Sponsor Protocol Number: ET-C-002-07 Start Date*: 2008-10-22
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)
    Medical condition: Translocation-Related Sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003686-17 Sponsor Protocol Number: WiNK Start Date*: 2020-07-03
    Sponsor Name:Glycostem Therapeutics BV
    Full Title: A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute my...
    Medical condition: acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 03:36:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA